Swipe Left For English News
上海,
2024年11月6日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司在明晟公司（MSCI）的环境、社会和公司治理（ESG）评级中获得AAA评级。蝉联此殊荣两年，有力地印证了药明生物在产品安全与质量、人力资本开发、企业治理和气候变化等关键议题上的卓越成就与领导力。
MSCI是全球权威的投资决策支持和服务提供商。其年度ESG评级旨在衡量一家企业应对长期可持续发展所面临挑战的韧性。针对特定关键议题，MSCI评估企业相较于其同行应对和管理各类ESG挑战的能力，进而对企业进行AAA（领导者）到CCC的评分。凭借杰出的可持续发展表现，药明生物于今年6月被纳入包括MSCI ESG领导者指数在内的多个ESG及气候变化指数。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸再次获得MSCI ESG最高评级，这是对我们在环境、社会和公司治理方面取得长足进展的极大认可。同时，最高评级也展现了我们聚焦公司愿景和使命，全面布局和高效执行ESG战略所取得的成绩。展望未来，我们将继续以此为动力，不断突破，引领全球生物药CRDMO行业的发展，携手共创一个更加健康、绿色的未来。
药明生物在联合国可持续发展目标的指导下，沿着可持续发展道路稳步向前。公司签署科学碳目标倡议（SBTi）承诺书，加入联合国全球契约组织（UNGC），以实际行动履行其对企业和社会可持续发展的承诺。
此外，公司的战略和举措得到了全球评级机构的广泛认可：获得国际权威企业可持续发展评估机构EcoVadis授予的“铂金”奖牌；入选标普道琼斯可持续发展世界指数和标普道琼斯新兴市场指数；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Receives AAA MSCI ESG Rating for Second Consecutive Year
Shanghai,
November 6, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings. This marks the second consecutive year the company has been recognized with the highest rating for its outstanding performance in the key areas of Product Safety and Quality, Human Capital Development, Corporate Governance and Corporate Behavior, and Climate Change.
MSCI is a leading provider of critical support tools and services for the global investment community. The purpose of its annual ESG Ratings is to measure a company's resilience to long-term ESG risks. Companies are rated on an industry-relative scale – from AAA (Leaders) to CCC (Laggards) – across the most relevant key issues, according to their exposure to ESG risks and how well they manage those risks relative to peers. Earlier this year, WuXi Biologics was also named to multiple ESG & Climate Change Indexes including the MSCI 2024 ESG Leaders Indexes for its outstanding sustainability performance.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are proud to once again achieve the highest rating from MSCI, a significant acknowledgement of our ESG accomplishments. This renewed AAA rating is a testament to the effective implementation of our ESG approaches and our unwavering commitment to sustainability – in alignment with the company's vision and mission. Moving forward, it will serve as an additional impetus for us to persist in our sustainability efforts, pushing the boundaries and demonstrating our leadership in the biologics CRDMO industry for a healthier and greener future.
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. To demonstrate its commitment, the company is a participant in the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi).
The company's efforts have been recognized by major ESG rating agencies. It has been awarded the distinguished Platinum Medal by EcoVadis; incorporated into the DJSI World Index and Emerging Markets Index; acclaimed as an Industry and Regional Top-Rated Company by Sustainalytics; featured in the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
